IMMP
Immutep Limited
NASDAQ · Healthcare · Biotechnology · AU
$0.36
−0.05%Year over year
Reported trailing growth
- Revenue
- +195.3%
- EBITDA
- -73.9%
- EBIT
- -59.3%
- EPS
- -18.8%
- Free cash flow
- -66.7%
- Operating cash flow
- -68.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +59.6%
- EBITDA
- -26.6%
- EBIT
- +35.1%
- Net income
- -26.3%
- EPS
- -26.2%
- Free cash flow
- +12.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026